Lupin, Novartis Drop Patent Dispute Over Lotrel

Law360, New York (September 10, 2009, 3:20 PM EDT) -- Novartis Corp. and Lupin Ltd. have dropped a long-running dispute over a patent for Lotrel, making the Indian generics manufacturer the latest to exit litigation over the pharmaceutical giant's billion-dollar hypertension drug.

Judge Garrett E. Brown Jr. of the U.S. District Court for the District of New Jersey signed off Wednesday on the joint stipulated order of dismissal.

Novartis promised to dismiss all of its claims that Lupin had infringed U.S. Patent Number 6,162,802 — the only unexpired patent covering the drug — with its 2006...
To view the full article, register now.